North America Liver Disease Treatment Market by Treatment Type and Disease Type : Opportunity Analysis and Industry Forecast, 2020–2027

North America Liver Disease Treatment Market by Treatment Type and Disease Type : Opportunity Analysis and Industry Forecast, 2020–2027

  • September 2020 •
  • 137 pages •
  • Report ID: 5983677 •
  • Format: PDF
North America Liver Disease Treatment Market by Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, and Chemotherapy) and Disease Type (Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders, and Others): Opportunity Analysis and Industry Forecast, 2020–2027

The North America liver disease treatment market accounted for $6,970 million in 2019, and is expected to reach $8,318 million by 2027, registering a CAGR of 5.2% from 2020 to 2027.
Medical care given to a patient suffering from liver diseases is termed as liver disease treatment. Furthermore, the treatment includes use of various drugs for different types of liver conditions. For instance, hepatitis B is a liver disease caused by a virus called hepatitis B virus (HBV). This condition is treated using antiviral drugs and can also be prevented by use of vaccines. Furthermore, other drugs that are used in treatment of hepatitis include immunoglobulin. Similarly, liver cancer is treated by using chemotherapy drugs and targeted therapy. In addition, some autoimmune liver related disorders are treated with the use of corticosteroids.
Furthermore, liver associated conditions also require liver transplant in many cases, where immunosuppressant drugs are used to prevent organ rejection. Thus, there are various types of liver treatments offered in the market such as anti-viral drugs, immunosuppressant drugs, vaccines, immunoglobulin, corticosteroid, targeted therapy, and chemotherapy drugs. In addition, these products are used to cure a range of liver diseases, which include hepatitis, autoimmune diseases, non-alcoholic fatty liver, and genetic disorders.
The major factors that contribute toward growth of the North America liver disease treatment market include increase in alcohol consumption & use of illegal drugs and rise in prevalence of liver disease. Furthermore, it is also a primary cause for worsening of various liver conditions, which require treatment. For instance, consumption of large quantity of alcohol can lead to liver condition called alcoholic hepatitis, which, in turn, leads to liver inflammation that requires treatment. Furthermore, factors such as surge in geriatric population and increase in government and non-government awareness programs also boost growth of the North America liver disease treatment market. For instance, older patients who acquire hepatitis C infection are more likely to develop cirrhosis in the coming years, owing to accelerated fibrosis rate and decreased immunity.
However, stringent approval process related to drugs and resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C of drugs restrict growth of the North America liver disease treatment market. For instance, approval processes require a huge capital investment. Moreover, any new drug manufacturing company that tries to enter into the market is bound to abide by these regulations. Therefore, these procedures are time consuming, which extends the time for their approval and commercialization and restricts growth of the market. Conversely, presence of strong pipeline products offer a lucrative opportunity for the market growth.
The North America liver disease treatment market is segmented on the basis of treatment type, disease type, and country to provide a detailed assessment of the market. By treatment type, the market is divided into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. By disease type, it is divided into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders and others. By country, it is classified into the U.S., Canada, and Mexico.Major players operating in the market include, Astellas Pharma Inc., Mylan N.V., AbbVie Inc., Merck & Co., Inc. (Merck Sharp & Dohme Corp.), Eli Lilly and Company, Pfizer Inc., Dynavax Technologies, Gilead Sciences, Inc., Bristol Myers Squibb, and Emergent BioSolutions (Cangene bioPharma).

KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global North America liver disease treatment market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments
• By Treatment Type
o Antiviral Drugs
o Immunosuppressants
o Vaccines
o Immunoglobulins
o Corticosteroids
o Targeted Therapy
o Chemotherapy
• By Disease Type
o Hepatits
o Autoimmune Diseases
o Ischemic Stroke
o Stenosis
o Others
• By Country
- U.S.
- Canada
- Mexico
• List of key players profiled in the report:
• Astellas Pharma Inc.
• Mylan
• AbbVie Inc.
• Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
• Eli Lilly and Company
• Dynavax Technologies
• Pfizer Inc.
• Gilead Sciences, Inc.,
• Bristol Myers Squibb
• Emergent BioSolutions (Cangene bioPharma)

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Sanofi
• F. Hoffmann-La Roche AG
• Novartis AG